A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Status:
Completed
Trial end date:
2014-02-28
Target enrollment:
Participant gender:
Summary
This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to
evaluate the safety and efficacy of MABT5102A in patients with mild to moderate Alzheimer's
Disease.